CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer

Tanaka,Tomohito; Terai,Yoshito; Kogata,Yuhei; Ashihara,Keisuke; Maeda,Kazuya; Fujiwara,Satoe; Yoo,Saha; Tanaka,Yoshimichi; Tsunetoh,Satoshi; Sasaki,Hiroshi; Kanemura,Masanori; Tanabe,Akiko; Ohmichi,Masahide

doi:10.3892/or.2015.4257

CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer

Authors:
- Tomohito Tanaka
- Yoshito Terai
- Yuhei Kogata
- Keisuke Ashihara
- Kazuya Maeda
- Satoe Fujiwara
- Saha Yoo
- Yoshimichi Tanaka
- Satoshi Tsunetoh
- Hiroshi Sasaki
- Masanori Kanemura
- Akiko Tanabe
- Masahide Ohmichi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki, Osaka 569-8686, Japan
Published online on: September 8, 2015 https://doi.org/10.3892/or.2015.4257
Pages: 2282-2288
Copyright: © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CD24, a small heavily glycosylated mucin-like glycosyl-phosphatidylinositol-anchored cell surface protein, plays an important role in the carcinogenesis of various human malignancies. However, its function in cervical cancer remains unclear. The aim of the present study was to evaluate the expression of CD24 clinicopathologically and to analyze its functional behavior biologically in cervical cancer. A total of 117 uterine cervical cancer tumors were immunohistochemically analyzed using a CD24 monoclonal antibody on paraffin blocks. We also examined whether CD24 enhanced the invasive activity or the Akt, ERK, NF-κB and MMP activity in a uterine cervical cancer cell line (CaSki) by a western blot analysis. The patients with enhanced CD24 expression had a higher rate of advanced clinical stage (50 vs. 16.5%, p<0.01), lymph node metastasis (34.6 vs. 14.3%) and lymphovascular involvement (65.4 vs. 20.4%, p=0.01), and a poor overall and disease-free survival (5-year survival rate: 62 vs. 86%, p=0.03). CD24 overexpression in CaSki cells resulted in activation of Cell Signaling proteins, including Akt, ERK, NF-κB and MMP-9. An invasion assay showed that CD24 overexpression in CaSki cells led to increased invasion ability. The CD24 overexpression also increased mRNA expression of Slug but not Snail. Moreover, the CD24 overexpression also decreased expression of E-cadherin and increased N-cadherin protein levels. Increased expression of CD24 may be associated with tumor progression and prognosis in patients with uterine cervical cancer. CD24 expression may therefore be used not only as a prognostic marker in uterine cervical cancer, but also as a target for the development of new therapeutic approaches.

View Figures

View References

1	Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ and Naghavi M: Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet. 378:1461–1484. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kay R, Rosten PM and Humphries RK: CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol. 147:1412–1416. 1991.PubMed/NCBI
3	Aigner S, Ruppert M, Hubbe M, Sammar M, Sthoeger Z, Butcher EC, Vestweber D and Altevogt P: Heat stable antigen (mouse CD24) supports myeloid cell binding to endothelial and platelet P-selectin. Int Immunol. 7:1557–1565. 1995. View Article : Google Scholar : PubMed/NCBI
4	Lee KM, Ju JH, Jang K, Yang W, Yi JY, Noh DY and Shin I: CD24 regulates cell proliferation and transforming growth factor β-induced epithelial to mesenchymal transition through modulation of integrin β1 stability. Cell Signal. 24:2132–2142. 2012. View Article : Google Scholar : PubMed/NCBI
5	Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, et al: CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood. 89:3385–3395. 1997.PubMed/NCBI
6	Sammar M, Aigner S and Altevogt P: Heat-stable antigen (mouse CD24) in the brain: Dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta. 1337:287–294. 1997. View Article : Google Scholar : PubMed/NCBI
7	King JB, von Furstenberg RJ, Smith BJ, McNaughton KK, Galanko JA and Henning SJ: CD24 can be used to isolate Lgr5⁺ putative colonic epithelial stem cells in mice. Am J Physiol Gastrointest Liver Physiol. 303:G443–G452. 2012. View Article : Google Scholar : PubMed/NCBI
8	Li J, Li C, Yuan H and Gong F: Clinical value of CD24 expression in retinoblastoma. J Biomed Biotechnol. 2012:1580842012. View Article : Google Scholar : PubMed/NCBI
9	Deng J, Gao G, Wang L, Wang T, Yu J and Zhao Z: CD24 expression as a marker for predicting clinical outcome in human gliomas. J Biomed Biotechnol. 2012:5171722012. View Article : Google Scholar : PubMed/NCBI
10	Hira SK and Manna PP: Down regulation of CD24 and HER-2/neu in breast carcinoma cells by activated human dendritic cell. Role of STAT3. Cell Immunol. 275:69–79. 2012. View Article : Google Scholar : PubMed/NCBI
11	Shi Y, Gong HL, Zhou L, Tian J and Wang Y: CD24: A novel cancer biomarker in laryngeal squamous cell carcinoma. ORL. J Otorhinolaryngol Relat Spec. 74:78–85. 2012. View Article : Google Scholar
12	Su N, Peng L, Xia B, Zhao Y, Xu A, Wang J, Wang X and Jiang B: Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer. Mol Cancer. 11:432012. View Article : Google Scholar : PubMed/NCBI
13	Zhu J, Zhang G and Lu H: CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance. Front Biosci. 4:2745–2751. 2012. View Article : Google Scholar
14	Liu C, Zheng S, Shen H, Xu K, Chen J, Li H, Xu Y, Xu A, Chen B, Kaku H, et al: Clinical significance of CD24 as a predictor of bladder cancer recurrence. Oncol Lett. 6:96–100. 2013.PubMed/NCBI
15	Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Höfler H and Becker KF: The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer. 98:489–495. 2008. View Article : Google Scholar
16	Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H and Jiang B: CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci. 101:112–119. 2010. View Article : Google Scholar
17	Kang KS, Choi YP, Gao MQ, Kang S, Kim BG, Lee JH, Kwon MJ, Shin YK and Cho NH: CD24⁺ ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochem Biophys Res Commun. 432:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, Cho JY, Yoon YS, Han HS and Cha BH: CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. Pancreas. 43:380–388. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D, Yuan Z, Wang F, Wu J, Zhang J, et al: Epithelial mesenchymal transition correlates with CD24⁺CD44⁺ and CD133⁺ cells in pancreatic cancer. Oncol Rep. 27:1599–1605. 2012.PubMed/NCBI
20	Lim J, Lee KM, Shim J and Shin I: CD24 regulates stemness and the epithelial to mesenchymal transition through modulation of Notch1 mRNA stability by p38MAPK. Arch Biochem Biophys. 558:120–126. 2014. View Article : Google Scholar : PubMed/NCBI
21	Jaggupilli A and Elkord E: Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clin Dev Immunol. 2012:7080362012. View Article : Google Scholar : PubMed/NCBI
22	Newman H, Shapira S, Spierer O, Kraus S, Rosner M, Pri-Chen S, Loewenstein A, Arber N and Barak A: Involvement of CD24 in angiogenesis in a mouse model of oxygen-induced retinopathy. Curr Eye Res. 37:532–539. 2012. View Article : Google Scholar : PubMed/NCBI
23	Rasheed ZA and Matsui W: Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol Hepatol. 27(Suppl 2): S15–S18. 2012. View Article : Google Scholar
24	Keysar SB and Jimeno A: More than markers: Biological significance of cancer stem cell-defining molecules. Mol Cancer Ther. 9:2450–2457. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kemper K, Grandela C and Medema JP: Molecular identification and targeting of colorectal cancer stem cells. Oncotarget. 1:387–395. 2010. View Article : Google Scholar
26	Zou GM: Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol. 217:598–604. 2008. View Article : Google Scholar : PubMed/NCBI
27	Tang J, Cai H, Lin L, Xie P, Zhong W and Tang M: Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma. Clin Transl Oncol. 15:541–547. 2013. View Article : Google Scholar
28	Wu JX, Zhao YY, Wu X and An HX: Clinicopathological and prognostic significance of CD24 overexpression in patients with gastric cancer: A meta-analysis. PLoS One. 9:e1147462014. View Article : Google Scholar : PubMed/NCBI
29	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
30	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
31	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
32	Maeda M, Johnson KR and Wheelock MJ: Cadherin switching: essential for behavioral but not morphological changes during an epithelium-to-mesenchyme transition. J Cell Sci. 118:873–887. 2005. View Article : Google Scholar : PubMed/NCBI